PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2026-05-06

Date Title Company
06-May-2026 AES Cleanroom Technology appoints John Groth as Chief Revenue Officer AES Cleanroom Technology
06-May-2026 Symeres appoints Henning Steinhagen as CEO to drive next phase of strategic growth  Symeres
06-May-2026 Environmental Monitoring Market: Industry Analysis, Size, Share, Trends, and Forecast (2025-2030) Medi-Tech Insights
06-May-2026 Immuno-Oncology (IO) Market In-depth Insights, Business Opportunities and Top Companies Analysis Forecast by 2030 Medi-Tech Insights
06-May-2026 Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference ACCESS Newswire
06-May-2026 Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress ACCESS Newswire
06-May-2026 Bulletin from The Annual General Meeting in Alligator Bioscience AB on 6 May 2026 ACCESS Newswire
06-May-2026 Takeda presenta resultados positivos preliminares del ensayo pivotal de fase 2/3 de TAK-881 en inmunodeficiencia primaria (IDP) Businesswire
06-May-2026 Spago Nanomedical's Phase I/IIa study Tumorad-01 Meets a Primary Endpoint and Provides Further Visible Tumor Uptake ACCESS Newswire
06-May-2026 Herbal Medicinal Products Market Growth - Market Analysis, Size, Share, Trends, Demand, Overview and Segment Forecast To 2031 Medi-Tech Insights
06-May-2026 Biosimulation Market Executive Summary, Segmentation, Review, Trends, Opportunities, Growth, Demand and Forecast to 2031 Medi-Tech Insights
06-May-2026 New scientific Article Published on TrkA-NAM ACD137 Against Osteoarthritic Pain ACCESS Newswire
06-May-2026 Invitation to the Presentation of Cantargia's Interim Report for Q1 2026 ACCESS Newswire
06-May-2026 Takeda anuncia resultados positivos de primeira linha do estudo clínico pivotal de Fase 2/3 do TAK-881 em Imunodeficiência Primária (IDP) Businesswire
06-May-2026 Holista Executes Binding JV for Collie Collagen Facility Holista Colltech Limited
06-May-2026 Takeda gibt positive Topline-Ergebnisse einer entscheidenden klinischen Phase-2/3-Studie mit TAK-881 bei primären Immundefekten (PID) bekannt Businesswire
06-May-2026 Takeda annonce les premiers résultats positifs d’un essai clinique pivot de phase 2/3 sur le TAK-881 dans le traitement des déficits immunitaires primaires (DIP) Businesswire
06-May-2026 Takeda宣布針對原發性免疫缺陷病(PID)開發的新藥TAK-881在二/三期臨床試驗中取得正面頂線結果 Businesswire
06-May-2026 Takeda宣布其用于治疗原发性免疫缺陷病(PID)的TAK-881关键性Ⅱ/Ⅲ期临床试验取得积极顶线结果 Businesswire
06-May-2026 Interim Report January - March 2026 ACCESS Newswire